Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weight loss pill shows promise in early trial

NCT ID NCT06854952

Disease control Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tested an experimental oral medication called TERN-601 in 167 adults with overweight or obesity. The goal was to see if it helps with weight loss over 12 weeks compared to a placebo. Participants did not have diabetes and had a stable weight before starting. The study is complete, and results will show how much weight was lost and if the drug is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

167 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Female or male aged 18 to 75 years 2. Body mass index (BMI) of: 1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2 OR 2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity 3. HbA1c \< 6.5% 4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss) Key Exclusion Criteria: 1. Have diabetes mellitus 2. Have obesity induced by medication or other diagnosed endocrinologic disorders 3. Have had or are planning surgical treatment or device-based therapy for obesity 4. Lifetime history of suicide attempt

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obesity

Contacts and locations

Locations

  • FALCON Research Site

    Birmingham, Alabama, 35294, United States

  • FALCON Research Site

    Homewood, Alabama, 35209, United States

  • FALCON Research Site

    Tucson, Arizona, 85712, United States

  • FALCON Research Site

    Spring Valley, California, 91978, United States

  • FALCON Research Site

    Port Orange, Florida, 32127, United States

  • FALCON Research Site

    Louisville, Kentucky, 40213, United States

  • FALCON Research Site

    Marrero, Louisiana, 70072, United States

  • FALCON Research Site

    Boston, Massachusetts, 02114, United States

  • FALCON Research Site

    Rochester, Minnesota, 55905, United States

  • FALCON Research Site

    City of Saint Peters, Missouri, 63303, United States

  • FALCON Research Site

    Beachwood, Ohio, 44122, United States

  • FALCON Research Site

    Medford, Oregon, 97504, United States

  • FALCON Research Site

    Dallas, Texas, 75230, United States

  • FALCON Research Site

    Houston, Texas, 77079, United States

  • FALCON Research Site

    San Antonio, Texas, 78229, United States

  • FALCON Research Site

    St. George, Utah, 84790, United States

  • FALCON Research Site

    Arlington, Virginia, 22206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.